BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cordis Corporation (JNJ) Release: Economic Model Presented at ISPOR 2011 Suggests That the Use of EXOSEAL Vascular Closure Device May Result in Important Cost Savings for U.S. Hospitals


11/9/2011 8:41:46 AM

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Results from a Cordis analysis presented at the 14th Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) congress in Madrid indicates use of EXOSEALTM Vascular Closure Devices in patients undergoing percutaneous coronary interventions (PCI) may result in important cost-savings for U.S. hospitals, as compared to combined use of ANGIO-SEALTM, MYNXTM, PERCLOSETM, and STARCLOSETM Vascular Closure Devices*(VCDs).

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES